Burghart, Lukas
Halilbasic, Emina
Schwabl, Philipp
Simbrunner, Benedikt
Stättermayer, Albert Friedrich
Petrenko, Oleksandr
Scheiner, Bernhard
Bauer, David
Pinter, Matthias
Boztug, Kaan
Mandorfer, Mattias
Trauner, Michael
Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 5 June 2021
Accepted: 26 November 2021
First Online: 11 December 2021
Declarations
:
: Dr Burghart, Dr Halilbasic, Dr Petrenko and Dr Boztug declare no conflict of interest. Dr Schwabl received speaking honoraria from Bristol-Myers Squibb and Boehringer-Ingelheim, consulting fees from PharmaIN and travel support from Falk. Dr Simbrunner received travel support from Abbvie and Gilead. Dr Stättermayer consults for, advises, and/or is on the speakers’ bureau for Boehringer Ingelheim, Gilead, and MSD. Dr Scheiner received travel support from Abbvie, Gilead and Ipsen. Dr Bauer received travel support from Abbvie and Gilead and has received speaker fees from Abbvie. Dr Mandorfer consults for, advises, is on the speakers’ bureau for, and/or received travel support from AbbVie, Bristol‐Myers Squibb, and Gilead. He consults for, advises, and/or is on the speakers’ bureau for W.L. Gore & Associates. Dr Pinter is an investigator for Bayer, BMS, Lilly, and Roche; he received speaker honoraria from Bayer, BMS, Eisai, Lilly, and MSD; he is a consultant for Bayer, BMS, Ipsen, Eisai, Lilly, MSD, and Roche; he received travel support from Bayer and BMS. Prof Trauner received grant support from Albireo, Cymabay, Falk, Gilead, Intercept, MSD, and Takeda, honoraria for consulting from BiomX, Boehringer Ingelheim, Falk, Genfit, Gilead, Intercept, Janssen, MSD, Novartis, Phenex, and Regulus, speaker fees from BMS, Falk, Gilead, Intercept and MSD, as well as travel support from Abbvie, Falk, Gilead and Intercept. Prof Reiberger received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche.